Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021

SELL
$2.16 - $3.18 $76,086 - $112,015
-35,225 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$2.89 - $4.22 $947 - $1,384
-328 Reduced 0.92%
35,225 $106,000
Q4 2020

Feb 16, 2021

BUY
$2.69 - $4.24 $45,364 - $71,503
16,864 Added 90.23%
35,553 $133,000
Q3 2020

Nov 12, 2020

BUY
$3.07 - $5.0 $6,793 - $11,065
2,213 Added 13.43%
18,689 $58,000
Q2 2020

Aug 13, 2020

BUY
$2.06 - $3.76 $10,304 - $18,807
5,002 Added 43.59%
16,476 $62,000
Q1 2020

May 14, 2020

SELL
$1.83 - $5.41 $1,259 - $3,722
-688 Reduced 5.66%
11,474 $26,000
Q4 2019

Feb 14, 2020

BUY
$4.03 - $6.5 $10,929 - $17,628
2,712 Added 28.7%
12,162 $63,000
Q3 2019

Nov 14, 2019

SELL
$2.8 - $12.85 $21,378 - $98,109
-7,635 Reduced 44.69%
9,450 $40,000
Q2 2019

Aug 14, 2019

SELL
$10.6 - $13.12 $45,654 - $56,507
-4,307 Reduced 20.13%
17,085 $201,000
Q1 2019

May 15, 2019

SELL
$9.96 - $13.44 $459,893 - $620,578
-46,174 Reduced 68.34%
21,392 $265,000
Q4 2018

Feb 14, 2019

SELL
$8.47 - $14.71 $758,327 - $1.32 Million
-89,531 Reduced 56.99%
67,566 $639,000
Q3 2018

Dec 21, 2021

BUY
$13.7 - $17.12 $1.15 Million - $1.43 Million
83,613 Added 113.78%
157,097 $2.26 Million
Q3 2018

Nov 14, 2018

SELL
$13.7 - $17.12 $694,576 - $867,966
-50,699 Reduced 40.83%
73,484 $1.06 Million
Q2 2018

Apr 21, 2020

BUY
$14.63 - $19.19 $261,277 - $342,714
17,859 Added 16.8%
124,183 $2 Million
Q2 2018

Aug 14, 2018

SELL
$14.63 - $19.19 $483,609 - $634,344
-33,056 Reduced 23.72%
106,324 $1.71 Million
Q1 2018

Oct 18, 2019

BUY
$16.06 - $25.35 $1.46 Million - $2.31 Million
91,059 Added 188.45%
139,380 $2.26 Million
Q1 2018

May 15, 2018

SELL
$16.06 - $25.35 $1.39 Million - $2.19 Million
-86,530 Reduced 64.17%
48,321 $783,000
Q4 2017

Feb 14, 2018

SELL
$10.51 - $17.22 $1.31 Million - $2.15 Million
-124,938 Reduced 48.09%
134,851 $2.26 Million
Q3 2017

Nov 14, 2017

BUY
$10.14 - $14.85 $2.63 Million - $3.86 Million
259,789
259,789 $3.63 Million

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $16.3M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.